Partnership Redefines the Patient Recruitment Process to Improve Efficiencies and Accelerate Time to MarketDecember 2, 2015 1:02 pm
hVIVO, the pioneer of human disease models, and Everbridge, a global provider of SaaS-based unified critical communications solutions, are joining forces to offer a next generation, virtual clinical trial platform that has the potential to transform the trial volunteer experience. The offering leverages secure clinical collaboration and telemedicine solutions from Everbridge to transition the trial volunteer experience from a sporadic notification process to an interactive, self-service community-based environment. The partnership provides access to personalized communications, secure dialog and remote data sharing between volunteers and their clinicians, which can help to streamline clinical trials and improve operational efficiencies.
Drug development remains a long and costly process, with clinical trials often taking 10-20 years. Trial recruitment activities play a pivotal role in defining time to market. According to the Tufts Center for the Study of Drug Development, study timelines are typically extended to twice their intended duration in order to meet enrollment levels. Despite this, 48 percent of trials still do not meet their recruitment targets. This novel, web-based clinical trial and volunteer communication platform will aid in maximising the engagement, retention and growth of volunteers enrolled for clinical trials through continuous 360 degree information collection and exchange via secure mobile and video communications. The platform promotes an ongoing dialog with volunteers, stimulating volunteer recruitment and avoiding trial delays.
Virtual recruitment and engagement for clinical trial patients aligns with the growing adoption of mobile health tools by both healthcare professionals and consumers. According to Forrester Research’s, November 2015 report: “Predictions 2016: The Empowered Patient,” “…mobile and wearables drive new patient interactions and new data. Smartphone adoption is at an all-time high for more than just Millennials. More than half of consumers have used their smartphones to get health information.” Clinical trial volunteers should likewise benefit from an easy-to-use, secure messaging and video solution that can transform their interactions over the course of the trial.
Enabling a better human experience is at the core of both Everbridge’s and hVIVO’s operations. The hVIVO platform tracks human disease in motion at the clinical, cellular and molecular detail, in addition to collecting patient reported information. This enables hVIVO to build the widest and deepest human samples-based data pool and support rational drug target and biomarker selection, creating more sustained value from this “client data.” The hVIVO human disease models platform can also bridge human biology and digital health, enabling unique insights into disease biology.
Everbridge is committed to driving innovation in healthcare by improving the clinical communication and collaboration experience for both clinicians and patients. The company’s unified critical communications platform and HipaaBridge, its secure messaging application designed for HIPAA compliance, can enable organizations to quickly and securely deliver the right message, to the right professional or patient, on the right device, at the right time.
The partnership between hVIVO and Everbridge will promote:
- Effective communication with the 100,000-person volunteer community
- Secure communication and collaboration between clinicians and volunteers
- Remote virtual health and telemedicine visits and data capture for volunteers and hVIVO’s clinical studies customers
- Better volunteer recruitment and clinical workflow efficiencies
“It’s incredibly gratifying to partner with an innovator like hVIVO to drive engagement and collaboration in the clinical trial process,” said Imad Mouline, CTO of Everbridge. “We look forward to providing a secure platform that can promote not only virtual health between clinicians and volunteers, but also can help drive broader efficiencies in clinical trial development and advancement.”
“Timely enrollment of the right subject is paramount for delivering today’s game-changing drugs on schedule,” said Kym Denny, hVIVO CEO. “hVIVO and Everbridge’s virtual clinical trial platform is designed to provide flexible study options for sponsors and an interactive volunteer experience, which can help improve efficiencies and bring innovative therapies to market more quickly, creating a win-win scenario for sponsors, volunteers and ultimately the patients.”
hVIVO and Everbridge plan to roll out this virtual clinical trial platform in phases, starting with the initial Volunteer Communication Platform in early 2016, followed by the full technology suite later in the year.
hVIVO plc (“hVIVO”) is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 2,000 volunteers for a range of leading industry, governmental and academic clients. For more information please visit www.hvivo.com, Facebook, and Twitter.
Everbridge is a global provider of SaaS-based unified critical communications solutions. During mission-critical business events or man-made or natural disasters, the Everbridge platform enables customers to quickly and reliably deliver the right message and reach the right people, on the right device, in the right location, at the right time. Utilizing sophisticated communications technologies, Everbridge has the ability to deliver and verify messages in near real-time to more than 100 different communication devices, in over 200 countries and territories, in multiple languages – all simultaneously. Everbridge is based in Boston and Los Angeles, with additional offices in San Francisco, Beijing and London. For more information, visit www.everbridge.com, read the company blog, www.everbridge.com/blog and follow on Twitter and Facebook.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Everbridge +1 781-373-9879
Jeff Benanto (Senior Manager, Marketing Communications and Customer Success)
Source for stats in the press release: http://csdd.tufts.edu/files/uploads/jan-feb_2013_ir_summary.pdf